Clearside Biomedical, Inc. (NASDAQ:CLSD) is a biopharmaceutical company focused on developing therapies to treat eye diseases. The company uses its proprietary SCS Microinjector to deliver drugs to the back of the eye. Despite its innovative approach, Clearside faces challenges in capital efficiency, as seen in its financial metrics.
Clearside's Return on Invested Capital (ROIC) is -177.13%, which is significantly lower than its Weighted Average Cost of Capital (WACC) of 16.81%. This negative ROIC indicates that the company is not generating enough returns to cover its cost of capital, suggesting inefficiencies in how it uses its capital.
In comparison, Cidara Therapeutics, Inc. (CDTX) has a ROIC of -25.45% and a WACC of 9.32%, resulting in a ROIC to WACC ratio of -2.73. While also negative, Cidara's metrics are less severe than Clearside's, indicating relatively better capital utilization.
Leap Therapeutics, Inc. (LPTX) shows a ROIC of -1170.57% against a WACC of 4.68%, leading to a ROIC to WACC ratio of -250.01. This highlights even greater inefficiencies compared to Clearside, suggesting significant challenges in generating returns.
Selecta Biosciences, Inc. (SELB) stands out with a positive ROIC of 6.80% and a WACC of 8.38%, resulting in a ROIC to WACC ratio of 0.81. This indicates that Selecta is generating higher returns to its capital, higher than its closest peers, making it a more attractive option for investors.
